Skip to main content
Advertisement
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
ADVERTISEMENT
Hongqu Xue, PhD
A Combination of Olanzapine and Samidorphan Has No Clinically Relevant Effect on QT Prolongation Up to Supratherapeutic Doses
Background: ALKS 3831, a combination of olanzapine and samidorphan (OLZ/SAM) in development for schizophrenia, is intended to mitigate olanzapine-associated weight gain. This thorough QT ...
Lisa L. von Moltke , MD, FCPP;
Lei Sun , PhD;
Sergey Yagoda , PhD, MD;
Hongqu Xue , PhD;
Randy Brown , MS;
Narinder Nangia , PhD;
Bhaskar Rege , PhD, BPharm;
Borje Darpo , MD, PhD;
David McDonnell , MD;
11/22/2019
Featured Webinar
Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications
Advertisement
Advertisement
Advertisement
Advertisement
Upcoming Events
November 6 – November 8
November 7 – November 10
November 8 – November 10
November 8
November 13 – November 16
November 14 – November 15
November 23 – November 24
December 4 – December 5
December 6 – December 7
December 9 – December 11
See Full Calendar
Advertisement
Advertisement
Advertisement